Beta-O2 Technologies

Implantable Bioreactor for Treating Type 1 Diabetes

Health Tech & Life Sciences
Non Active, Aug 2025 ceased to operate

Company Overview

Snapshot

Founded in January 2004, Beta-O2 Technologies operates with 11–50 employees. The company has secured $8.22M in total capital across 6 funding rounds from 5 investors. In August 2025, the company ceased operations.

Business overview

Beta-O2 Technologies is a biomedical company focused on developing the Air, a proprietary implantable bioreactor designed for the treatment of patients with type 1 diabetes. This small medical device, implanted through a minimally invasive procedure, contains islets of Langerhans and aims to eliminate the need for insulin injections and continuous glucose monitoring, while also reducing the risk of hypoglycemic episodes. The device requires periodic air refills due to its living cell components, positioning the company within the Health Tech & Life Sciences sector, specifically in medical devices and biomaterials.

Strategic signal

Beta-O2 Technologies ceased operations in August 2025, indicating a significant and definitive shift in its corporate trajectory. This event signals to investors and innovation teams that the company is no longer actively pursuing its mission in the biomedical space, marking a critical endpoint for its implantable bioreactor technology for type 1 diabetes.

Company Intelligence Q&A

What is the primary focus of Beta-O2 Technologies?
Beta-O2 Technologies develops the Air, a proprietary implantable bioreactor for treating type 1 diabetes. This device aims to free patients from insulin injections and continuous glucose monitoring.
When was Beta-O2 Technologies founded?
Beta-O2 Technologies was founded in January 2004.
What was the latest significant operational update for Beta-O2 Technologies?
Beta-O2 Technologies ceased operations in August 2025.
Which investors participated in Beta-O2 Technologies' March 2004 funding round?
In March 2004, Beta-O2 Technologies received funding from SCP Vitalife and Heznek Fund.
What was the total capital raised by Beta-O2 Technologies?
Beta-O2 Technologies raised a total of $8.22M across 6 funding rounds.

External links